Hidradenitis Suppurativa
DOI: 10.1007/978-3-540-33101-8_11
|View full text |Cite
|
Sign up to set email alerts
|

Bacteriology of Hidradenitis Suppurativa

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
14
1

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 11 publications
(15 citation statements)
references
References 43 publications
0
14
1
Order By: Relevance
“…The latter, notably, is, in combination with rifampicin, one of the most widely recommended first-line therapies for HS. Tetracycline is described as an alternative antibiotic agent in HS therapy [26]. However, our data showed a resistance rate of almost 33%.…”
Section: Discussioncontrasting
confidence: 51%
See 1 more Smart Citation
“…The latter, notably, is, in combination with rifampicin, one of the most widely recommended first-line therapies for HS. Tetracycline is described as an alternative antibiotic agent in HS therapy [26]. However, our data showed a resistance rate of almost 33%.…”
Section: Discussioncontrasting
confidence: 51%
“…In addition to the reduction of bacterial growth, some antibiotic agents (e.g. tetracycline, clindamycin, and minocycline) also have immunomodulatory and anti-inflammatory properties [26,27,28]. …”
Section: Discussionmentioning
confidence: 99%
“…Although numerous bacteria are found in association with hidradenitis suppurativa (Oprica & Nord 2006) they are not considered to be causative. Streptococcus milleri is frequently found in the lesions and there is some response to antibiotic agents.…”
Section: Hidradenitis Suppurativamentioning
confidence: 99%
“…21,26,27 These findings are supported by the observation that during the proinflammatory phase of HS, neutrophilic infiltration is accompanied by the release of TNF-alfa, which may mediate HS-associated keratinocyte proliferation. 9,16,26,[28][29][30] Observational data, case reports, and limited nonrandomized studies in the literature highlight the potential clinical use of IFX in patients with moderate to severe HS and underscore the need for a controlled, randomized prospective clinical trial. 26,28,[31][32][33][34][35] We report here the results of a single-center, prospective, randomized double-blind, placebo-controlled, open-label crossover trial to examine the efficacy and safety of IFX and placebo on patients with moderate to severe HS.…”
mentioning
confidence: 94%
“…7 In moderate to severe cases, further tissue destruction leads to draining pustules, subcutaneous sinus tracts, and extensive fibrous scars. [8][9][10] HS predominately occurs in skin folds bearing terminal hairs and apocrine glands, typically affecting the axillae, genitofemoral region of female patients, and anogenital region of male patients. 1,8 The lesions are invariably painful, unsightly, odorous, and can have a devastating effect on the patient's quality of life both as a physical ailment and social concern.…”
mentioning
confidence: 99%